Last 21.25 GBp
Change Today +0.75 / 3.66%
Volume 252.1K
EKF On Other Exchanges
As of 11:35 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

ekf diagnostics holdings plc (EKF) Snapshot

21.25 GBp
Previous Close
20.50 GBp
Day High
21.25 GBp
Day Low
21.25 GBp
52 Week High
02/7/14 - 38.00 GBp
52 Week Low
12/19/14 - 19.50 GBp
Market Cap
Average Volume 10 Days
-0.0084 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ekf diagnostics holdings plc (EKF) Related Businessweek News

No Related Businessweek News Found

ekf diagnostics holdings plc (EKF) Details

EKF Diagnostics Holdings plc is engaged in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the United Kingdom, the United States, Germany, Poland, Russia, Ireland, and Asia. The company offers near patient analyzers for the measurement of glucose, lactate, hemoglobin, hematocrit, and HbA1c. Its products include glycated hemoglobin analyzers, such as Quo-Test, Quo-Lab, and Biosen HbA1c analyzers for monitoring diabetes; hemoglobin analyzers consisting of Hemo Control and Hemo Vet, which are point of care devices to provide results for hemoglobin and hematocrit, as well as STAT-Site M Hgb, a hand-held device for blood screening programs; and glucose analyzers comprising Biosen C-Line and S-Line glucose and lactate analyzers, and Lactate Scout+, a hand-held lactate analyzer. The company also provides rapid testing services, including pregnancy tests, such as True20, QuPID, and QuStick for urine only or urine and serum pregnancy testing; and infectious diseases tests, such as H. Pylori, RELY Mono, RELY and Strep A, and QuStick for the detection of pathonogenic micro-organisms, such as bacteria, parasites, viruses, and fungi. In addition, it offers clinical chemistry reagents; and biomarker diagnostic kits used by researchers and clinicians, as well as molecular diagnostic test kits, which are focused on applications within oncological research. The company sells its products to GP surgeries, pharmacies, blood banks, sports clinics, hospitals, and laboratories through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

330 Employees
Last Reported Date: 02/26/14
Founded in 1990

ekf diagnostics holdings plc (EKF) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 297.0K GBP
Executive Chairman
Total Annual Compensation: 45.0K GBP
Finance Director, Secretary and Executive Dir...
Total Annual Compensation: 19.0K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 214.0K GBP
Compensation as of Fiscal Year 2013.

ekf diagnostics holdings plc (EKF) Key Developments

EKF Diagnostics Holdings plc Provides Unaudited Earnings Guidance for the Full Year Ending December 31, 2014

EKF Diagnostics Holdings plc provided unaudited earnings guidance for the full year ending December 31, 2014. For the period, the company's financial results are expected to be below consensus expectations. The company expects that unaudited revenues will show at least an increase of 24% on the previous year to £39.5 million. Unaudited adjusted EBITDA is expected to be at least 29% up on the previous year at £6.2 million. Excluding the effect of exchange rates, revenue would have been expected to be up at least 30% year on year and adjusted EBITDA would have been expected to be up at least 37%.

EKF Diagnostics Enters into Multi-Year, Collaborative Relationship with Joslin Diabetes Center in Support of the Ongoing Clinical and Commercial Translation

EKF Diagnostics has entered a multi-year, collaborative relationship with Joslin Diabetes Center in support of the ongoing clinical and commercial translation of TNFR1 & 2 biomarkers. These novel biomarkers can help identify patients with Type 1 and Type 2 diabetes that are at an increased risk of developing end stage renal disease (ESRD), up to ten years in advance. The new agreement between Joslin, an affiliate of Harvard Medical School, and EKF is part of Joslin's Corporate Liaison Program (CLP). This program seeks to accelerate development, validation and market introduction of unique products and solutions that advance treatments and care for diabetes and its complications. As globally recognized leaders in the field of diabetes research, Joslin has created the CLP in order to foster industry partnerships within the pharmaceutical, biotechnology, food and device industries. The role of the CLP is to help engage corporate partners, such as EKF, with Joslin's capabilities in advisory services, clinical expertise, and research infrastructure. This enables Joslin to work closely with an industry partner to customize its offerings towards a defined product program or a range of corporate priorities within diabetes management.

EKF Diagnostics Holdings plc Enters into Two Year Research Collaboration with Massachusetts General Hospital to Develop PointMan Assays to Effectively Detect Treatable Cancer Mutations in Blood Samples

EKF Diagnostics Holdings plc announced that it has entered into two year research collaboration with Massachusetts General Hospital to develop PointMan assays that can effectively detect treatable cancer mutations in blood samples. The collaboration agreement has been signed following a detailed evaluation of PointMan DNA enrichment technology by MGH and will cover a two year long project focusing on lung, breast and skin cancer. MGH will use PointMan DNA enrichment technology for the detection of genetic variation in circulating tumour cells (CTCs) isolated from a patient's blood using MGH's CTC-Chip instrument. CTCs are shed by primary tumors allowing the cancer to metastasise. CTCs are extremely rare in whole blood and their isolation and characterisation could offer clinicians a routine method with which to diagnose, treat and monitor the progress of various cancers. The main difficulty in successfully analysing CTCs has been the ability to detect low level mutations sufficiently and to create assays that are sensitive enough to provide meaningful data; difficulties which PointMan may be able to effectively overcome. EKF Molecular will design and develop high sensitivity assays which will be utilised by MGH with a view to clinically validating PointMan in the detection of existing and novel mutations, a major step towards the improvement of patient outcomes in the hospital.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EKF:LN 21.25 GBp +0.75

EKF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EKF.
View Industry Companies

Industry Analysis


Industry Average

Valuation EKF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 0.7x
Price/Cash Flow 6,077.4x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EKF DIAGNOSTICS HOLDINGS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at